BTAI:NSD-BioXcel Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 25.95

Change

+0.36 (+1.41)%

Market Cap

USD 0.71B

Volume

0.20M

Avg Analyst Target

USD 75.00 (+189.02%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-6.99 (-1.98%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.86 (+3.61%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+2.52 (+0.44%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-3.26 (-1.62%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.12 (+0.27%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+10.83 (+3.42%)

USD29.25B N/A N/A
SGEN Seagen Inc

+0.85 (+0.55%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

-0.99 (-2.59%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

-0.98 (-0.55%)

USD21.03B N/A N/A

ETFs Containing BTAI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.83% 15% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.83% 15% F 7% F
Trailing 12 Months  
Capital Gain -45.07% 21% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.07% 21% F 7% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 130.00% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 130.00% 92% A- 95% A
Risk Return Profile  
Volatility (Standard Deviation) 223.23% 10% F 6% F
Risk Adjusted Return 58.24% 84% B 75% C
Market Capitalization 0.71B 68% D+ 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.81 44% F 38% F
Price / Cash Flow Ratio -10.72 63% D 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -72.21% 39% F 23% F
Return on Invested Capital -70.46% 31% F 11% F
Return on Assets -40.41% 19% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.53 43% F 29% F
Short Percent 15.57% 10% F 10% F
Beta 1.07 67% D+ 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector